| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 公司专注于医药健康产业，主要从事中成药品、化学制剂药品、化学原料药的研发、生产和销售。公司的主要产品包括止咳宝片、感冒灵颗粒、血塞通分散片、银杏叶分散片、益心舒颗粒、铝碳酸镁咀嚼片、枫蓼肠胃康片、奥美拉唑肠溶胶囊、皮肤病血毒丸、小儿咳喘灵颗粒、金匮肾气片、降糖舒丸等。 公司核心产品止咳宝片有一百多年历史，在清代末期就享有盛誉，具有“宣肺祛痰、止咳平喘”之功效。经临床总结有三大特点：一是对各类型的慢性咳嗽有显著效果，对止咳、化痰、平喘疗效十分明显，临控+显效率为73%，总有效率为93%；二是毒副作用低，疗程短、见效快、服药方便；三是对虚寒型和痰湿型咳喘治疗效果最好，总有效率分别是100%及95%。 止咳宝片属于中成药止咳化痰类药品，根据南方医药经济研究所米内网数据库的统计数据，公司的止咳宝片连续多年位列止咳类口服药前十大品牌。同时，公司已启动皮肤病血毒丸的临床试验，公司将通过核心品种的临床研究或真实世界研究，推动公司特色中药品种（含止咳宝片、皮肤病血毒丸、降糖舒丸等）成长为中药大品种，提升公司的经营业绩和抗风险能力。 | ||||||||||||||||||||||||
| Main Business | 主要从事中成药品、化学制剂药品、化学原料药的研发、生产和销售 | ||||||||||||||||||||||||
| Legal Representative | 许丹青 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 陈习良 | ||||||||||||||||||||||||
| Solicitors | 国浩律师（深圳）事务所 | ||||||||||||||||||||||||
| Auditors | 大信会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 0750-5627588 | ||||||||||||||||||||||||
| Fax No | 0750-5627000 | ||||||||||||||||||||||||
| Website | www.tczy.com.cn | ||||||||||||||||||||||||
| ty002728@vip.163.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 31/07/2014 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 0.770 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 0.500 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 5.510 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 3.510B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |